Study guide

15.2 Adverse Drug Reactions

CRNI® Exam Study Guide Certified Registered Nurse Infusion

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application & Testing Windows 1.3 Scoring, Results & Recertification

2 Anatomy & Physiology for Infusion Practice

2.1 Vascular Anatomy & Physiology for Infusion 2.2 Body Positioning for Catheter Insertion & Removal 2.3 Vein Selection & Patient Assessment

3 Infection Prevention & Control

3.1 Infection Prevention Strategies & Standard Precautions 3.2 Chain of Infection in Infusion Practice 3.3 Bloodstream Infections & CLABSI Prevention 3.4 Phlebitis: Prevention, Grading & Management

4 Phlebotomy in Infusion Practice

4.1 Blood Sampling & Blood Culture Collection 4.2 Therapeutic Phlebotomy

5 Infusion Equipment & Technology

5.1 Solution Containers, Administration Sets & Filters 5.2 Add-on Devices, Administration Devices & Closed Systems 5.3 Vein Location Devices, Navigation Tools & Securement

6 Peripheral Venous Access Devices

6.1 Short & Long Peripheral Intravenous Catheters 6.2 Midline Catheters 6.3 Peripheral Device Selection Criteria

7 Central Venous Access Devices

7.1 Peripherally Inserted Central Catheters (PICC) 7.2 Non-tunneled Central Venous Catheters 7.3 Tunneled Central Venous Catheters 7.4 Implanted Ports

8 Alternate Access Routes & Device Maintenance

8.1 Subcutaneous Infusion Access 8.2 Intraosseous Access 8.3 Device Maintenance & Care Protocols

9 Special Populations in Infusion Therapy

9.1 Older Adults & Chronic Renal Conditions 9.2 Pediatrics, Immunocompromised, Oncology & Bariatrics

10 Device-Related Complications

10.1 Infiltration & Extravasation 10.2 Catheter Occlusion 10.3 Thrombosis, Air Embolism & Device-Related Systemic Events

11 Fluid & Electrolyte Balance

11.1 Body Composition & Fluid Balance 11.2 Fluid Volume Excess & Deficit 11.3 Electrolyte Disorders 11.4 Maintenance & Replacement Fluids

12 Parenteral Nutrition

12.1 Parenteral Nutrition: Solution Composition 12.2 PN Infectious, Metabolic & Mechanical Complications

13 Anti-infectives, Blood Products & Biologics

13.1 Anti-infective Infusion Therapy 13.2 Blood Products & Transfusion Therapy 13.3 Biologics & Immunologic Therapies

14 Antineoplastic, Cardiovascular & Pain Infusions

14.1 Antineoplastic Infusion Therapy 14.2 Cardiovascular Infusions 14.3 Pain Management Infusions

15 Therapy-Related Complications & Hazardous Drugs

15.1 Rate-Related Complications 15.2 Adverse Drug Reactions 15.3 Hazardous Drug Exposure & Waste Disposal

16 Professional Practice, Documentation & Quality

16.1 Assessment, Consent & Collaborative Care Planning 16.2 Documentation, Laws & Regulatory Agencies 16.3 Evidence-Based Practice & Performance Improvement

15.2 Adverse Drug Reactions

Key Takeaways Explain This Topic AI

Type I hypersensitivity/anaphylaxis is IgE-mediated and can progress to multi-system collapse; anaphylactoid reactions can look similar but are not IgE-triggered—both can be life-threatening and need urgent treatment based on severity.

Cytokine-release reactions and delayed hypersensitivities expand the ADR spectrum beyond immediate allergy; grade reactions as mild, moderate, or severe to guide stop vs supportive vs emergency pathways.

For anaphylaxis: STOP the drug, maintain airway, give epinephrine IM as first-line, establish/maintain IV access with NS, and activate rapid response—do not delay epinephrine for antihistamines alone.

Document the reaction thoroughly and update allergy labeling so the agent is not re-exposed casually; rechallenge occurs only under controlled protocols with appropriate setting and preparedness.

Extravasation is a local tissue injury from leakage; systemic ADRs are body-wide immune or pharmacologic responses—do not treat a swollen cool site as anaphylaxis or delay stopping a systemic reaction to focus only on the IV site.

Last updated: August 2026

Adverse drug reactions in the infusion context

Quick Answer: An adverse drug reaction (ADR) is a harmful or unintended response to a medication at normal doses or during therapeutic use. In infusion nursing, prioritize recognition , severitying severity , stopping the culprit infusion , and escalating for airway/breathing/circulation threats. Anaphylaxis treatment centers on intramuscular epinephrine plus airway support and IV fluids—not antihistamines alone.

Domain 3I.2 sits next to rate-related problems and hazardous-drug safety because many ADRs present during or shortly after parenteral administration. The exam expects more than “call the doctor”: it expects a ordered emergency sequence , correct allergy documentation , and the ability to separate local tissue injury from systemic reaction .

  • Type I hypersensitivity and anaphylaxis vs anaphylactoid reactions
  • Type I (IgE-mediated) hypersensitivity

Type I reactions involve antigen cross-linking of IgE on mast cells and basophils with rapid release of histamine and other mediators. Prior sensitization is typical (though patients may not recall a prior mild exposure). Clinical spectrum ranges from urticaria to anaphylaxis .

Anaphylaxis is a severe, potentially fatal, systemic hypersensitivity reaction usually of rapid onset. Clues include:

  • Skin/mucosal: urticaria, pruritus, flushing, angioedema
  • Respiratory: dyspnea, wheeze, stridor, throat tightness, hypoxia
  • Cardiovascular: hypotension, tachycardia, syncope, shock
  • Gastrointestinal: crampy pain, vomiting, diarrhea
  • Sense of impending doom

Not every feature must be present. Hypotension plus known allergen exposure, or skin findings plus respiratory compromise, should trigger anaphylaxis thinking.

Anaphylactoid (non–IgE-mediated) reactions

Anaphylactoid reactions produce a similar clinical picture through direct mast-cell activation or other non–IgE pathways (examples in concept: some contrast reactions, rapid vancomycin flushing-syndrome physiology, certain opioid histamine effects). From the bedside, severe presentations are treated supportively like anaphylaxis when airway or perfusion is threatened. Mechanism matters later for allergy labeling, skin testing, and rechallenge decisions—but do not withhold epinephrine in a crashing patient because you are debating IgE vs non-IgE.

  • Feature Type I anaphylaxis Anaphylactoid
  • Classic trigger path IgE-mediated Non–IgE / direct mediator release
  • Looks like Multi-system allergic emergency Can look nearly identical
  • Immediate care when severe STOP drug, epinephrine IM, ABCs Same severity-based emergency care
  • Follow-up Allergy labeling, avoid re-exposure Mechanism-informed labeling and future protocols
  • Cytokine release and delayed reactions
  • Cytokine-release reactions

Cytokine release (including cytokine release syndrome concepts with some biologics and immunotherapies) may present with fever, chills, rigors, myalgias, hypotension, and capillary leak–type physiology during or after infusion. These are not always classic IgE allergy. Management is protocol-driven: slow or stop the infusion, supportive care, antipyretics, fluids, and sometimes corticosteroids or other ordered therapies per specialty pathway. Know that first doses and dose escalations are higher-risk windows for many biologics.

Delayed reactions

Not all ADRs are immediate. Delayed hypersensitivities (e.g., delayed maculopapular rashes, some severe cutaneous adverse reactions, serum sickness–like patterns) may appear hours to days later. Nursing implications: teach patients what to report after discharge, document timed onset carefully, and do not restart the agent without provider/allergy guidance. Delayed severe cutaneous reactions (e.g., concepts of SJS/TEN) are emergencies requiring immediate drug cessation and specialty care—exam stems may test “stop and escalate,” not home antihistamine alone.

Grading: mild, moderate, severe

Use a practical severity frame (facility infusion-reaction scales may be more granular):

Grade Examples Typical direction

Mild Isolated flushing, mild pruritus, low-grade temperature rise without respiratory/CV compromise Often stop or slow, assess, treat symptoms per protocol, possible cautious resume if ordered

Moderate Generalized urticaria, moderate rigors, nausea, mild bronchospasm responsive to treatment Stop infusion, treat, notify provider; resume only if explicitly appropriate

Severe Hypotension, significant bronchospasm/stridor, angioedema with airway threat, anaphylaxis, severe cytokine storm physiology Emergency pathway: stop drug, epinephrine when anaphylaxis, rapid response, do not casually rechallenge

Grading drives decisions. Mild isolated itching is not managed the same as stridor and hypotension. Document grade language your facility uses so the next clinician understands severity.

Anaphylaxis emergency pathway (high-yield sequence)

When anaphylaxis is suspected during an infusion:

STOP the drug/infusion immediately. Do not leave the culprit running “a little longer.”

Call for help / activate rapid response or code per severity and setting.

Maintain airway ; high-flow oxygen as indicated; prepare for advanced airway if obstruction evolves.

Epinephrine IM (anterolateral thigh preferred conceptually) is first-line for anaphylaxis—do not delay for IV start, steroids, or antihistamines.

Place patient supine (or position for comfort/respiration); elevate legs if hypotensive and no respiratory contraindication per emergency guidance.

Establish/maintain IV access and infuse 0.9% sodium chloride for hypotension as ordered/protocol.

Remove other ongoing allergens if identifiable; monitor continuously (SpO2, BP, HR, mentation).

Adjuncts after epinephrine as ordered: antihistamines, bronchodilators, corticosteroids—these are adjuncts , not substitutes for epinephrine in true anaphylaxis.

Observe for biphasic recurrence; admit/observe per protocol even if early improvement occurs.

Document and update allergy records before the next shift administers the same agent.

  • Exam traps for anaphylaxis
  • Giving diphenhydramine first and “watching” while the patient is hypotensive and wheezing
  • Leaving the infusion at a “keep-open” rate of the same drug

Confusing mild vancomycin flushing syndrome with full anaphylaxis—or the reverse: dismissing hypotension and stridor as “just flushing syndrome”

Forgetting IM epinephrine route concepts in favor of slow IV push epinephrine without emergency indication/protocol

Documentation, allergy labeling, and rechallenge

Documentation must capture: drug name and dose, lot if relevant, route and rate, exact time of onset, signs/symptoms by system, interventions and times, patient response, notifications, and teaching. Vague notes (“had a reaction”) fail the next caregiver.

Allergy labeling in the EHR and medication administration record should reflect the agent, reaction type/severity when known, and date. Distinguish true allergy from intolerance (e.g., nausea alone) when the history supports it—but when anaphylaxis occurred, label clearly to prevent re-exposure.

Rechallenge (including desensitization) is not a bedside improvisation . It occurs only under controlled protocols —often allergy/immunology or specialty order sets—in settings prepared for anaphylaxis. Home or casual unit rechallenge after severe reaction is an exam wrong answer.

  • Distinguishing extravasation (local) from systemic ADR
  • This distinction is a CRNI favorite because both can present “during the IV med.”
  • Extravasation / infiltration (local) Systemic ADR (e.g., anaphylaxis)
  • Primary problem Drug/fluid in tissue , not vessel Drug in circulation triggering body-wide response
  • Local site Swelling, coolness, blanching, leakage, burning at site Site may look normal

Systemic signs Usually absent early (unless large volume overload or severe pain response) Urticaria, bronchospasm, hypotension, GI symptoms, etc.

First action STOP infusion; aspirate residual if vesicant pathway; do not force flush STOP drug; ABCs; epinephrine IM if anaphylaxis

Wrong move Treating only with epinephrine while ignoring tissue injury pathway Focusing only on warm compresses while the patient is in anaphylactic shock

Both require stopping the infusion . After stop, branch: tissue pathway vs systemic emergency pathway . Some patients can have both (e.g., allergic reaction plus a bad site)—treat the life threat first while protecting tissue.

  • Prevention and readiness
  • Allergy history before high-risk infusions; reconcile EHR allergies
  • First-dose monitoring policies for agents with known reaction risk
  • Bedside emergency equipment: oxygen, suction, epinephrine, airway tools, IV fluids

Know which infusions need premedication per protocol (not as a substitute for rate control or true allergy avoidance)

Educate patients to report itching, throat tightness, dyspnea, or dizziness immediately

Master the mental model: classify the reaction → grade severity → stop the drug → treat anaphylaxis with epinephrine-first care when indicated → document and label → rechallenge only under protocol → never confuse local extravasation with systemic ADR. That model converts chaotic bedside events into defensible CRNI answers.